Sight Sciences to Present at the Morgan Stanley Global Healthcare Conference
Sight Sciences, Inc. (Nasdaq: SGHT) is a technology company dedicated to eyecare, focusing on the development and commercialization of innovative interventional technologies that enhance the standard of care. The Company has announced its participation in the upcoming Morgan Stanley Global Healthcare Conference.
Event Details
The management team at Sight Sciences is set to present on a scheduled date. Those interested can access a live and archived webcast of the presentation in the "Investors" section of the company’s website.
About Sight Sciences
Sight Sciences is devoted to transforming patient care and enhancing lives through cutting-edge eyecare technology. The Company utilizes both minimally invasive and non-invasive techniques to tackle the root causes of common eye diseases, aiming to create more effective treatment options.
Innovative Technologies
The OMNI Surgical System, developed by the Company, is an implant-free technology for glaucoma surgery that aims to lower intraocular pressure in adults suffering from primary open-angle glaucoma. It has received CE Mark approval for additional procedures related to open-angle glaucoma. Additionally, the SION Surgical Instrument is specifically designed for ophthalmic surgeries, allowing for effective excision of trabecular meshwork.
TearCare System
Furthermore, Sight Sciences provides the TearCare System, which is cleared for use in the United States to deliver localized heat therapy for evaporative dry eye disease caused by meibomian gland dysfunction (MGD). This system enables physicians to remove gland obstructions, addressing a primary contributor to dry eye disease.
Investor and Media Contacts
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
Frequently Asked Questions
What is the purpose of Sight Sciences' presentation at the conference?
The presentation aims to highlight the Company's innovative eyecare technologies and advancements within the industry.
What technologies does Sight Sciences focus on?
The Company specializes in developing interventional technologies for treating glaucoma and dry eye diseases.
How does the OMNI Surgical System work?
The OMNI Surgical System is engineered for implant-free glaucoma surgery, designed to decrease intraocular pressure.
Is the TearCare System widely available?
Yes, the TearCare System has received 510(k) clearance for use in the United States.
Who can be contacted for more information about investors and media?
For inquiries related to investors, reach out to Philip Taylor at Gilmartin Group, and for media questions, contact the Company's PR team.